Susann Stollberg1, Daniel Kämmerer2, Elisa Neubauer1, Stefan Schulz1, Ingrid Simonitsch-Klupp3, Barbara Kiesewetter4, Markus Raderer4, Amelie Lupp5. 1. Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Drackendorfer Str. 1, 07747, Jena, Germany. 2. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. 3. Clinical Institute for Pathology, University of Vienna, Vienna, Austria. 4. Department of Internal Medicine I, University of Vienna, Vienna, Austria. 5. Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Drackendorfer Str. 1, 07747, Jena, Germany. Amelie.Lupp@med.uni-jena.de.
Abstract
PURPOSE: Whereas the different somatostatin receptor (SSTR) subtypes and the chemokine receptor CXCR4 are known to be expressed in a wide variety of human malignancies, comprehensive data are still lacking for MALT-type lymphomas. METHODS: Overall, 55 cases of MALT-type lymphoma of both gastric and extragastric origin were evaluated for the SSTR subtype and CXCR4 expression by means of immunohistochemistry using novel monoclonal rabbit antibodies. The stainings were rated by means of the immunoreactive score and correlated with clinical data. RESULTS: While the CXCR4 was detected in 92 % of the cases investigated, the SSTR subtypes were much less frequently present. The SSTR5 was expressed in about 50 % of the cases, followed by the SSTR3, the SSTR2A, the SSTR4 and the SSTR1, which were present in 35, 27, 18 or 2 %, respectively, of the tumors only. Gastric lymphomas displayed a significantly higher SSTR3, SSTR4 and SSTR5 expression than extragastric tumors. A correlation between CXCR4 and Ki-67 expression was seen in gastric lymphomas, whereas primarily in extragastric tumors SSTR5 negativity was associated with poor patient outcome. CONCLUSIONS: The CXCR4 may serve as a promising target for diagnostics and therapy of MALT-type lymphomas, while the SSTRs appear not suitable in this respect.
PURPOSE: Whereas the different somatostatin receptor (SSTR) subtypes and the chemokine receptor CXCR4 are known to be expressed in a wide variety of humanmalignancies, comprehensive data are still lacking for MALT-type lymphomas. METHODS: Overall, 55 cases of MALT-type lymphoma of both gastric and extragastric origin were evaluated for the SSTR subtype and CXCR4 expression by means of immunohistochemistry using novel monoclonal rabbit antibodies. The stainings were rated by means of the immunoreactive score and correlated with clinical data. RESULTS: While the CXCR4 was detected in 92 % of the cases investigated, the SSTR subtypes were much less frequently present. The SSTR5 was expressed in about 50 % of the cases, followed by the SSTR3, the SSTR2A, the SSTR4 and the SSTR1, which were present in 35, 27, 18 or 2 %, respectively, of the tumors only. Gastric lymphomas displayed a significantly higher SSTR3, SSTR4 and SSTR5 expression than extragastric tumors. A correlation between CXCR4 and Ki-67 expression was seen in gastric lymphomas, whereas primarily in extragastric tumorsSSTR5 negativity was associated with poor patient outcome. CONCLUSIONS: The CXCR4 may serve as a promising target for diagnostics and therapy of MALT-type lymphomas, while the SSTRs appear not suitable in this respect.
Authors: Markus Raderer; Berthold Streubel; Stefan Woehrer; Andreas Puespoek; Ulrich Jaeger; Michael Formanek; Andreas Chott Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531
Authors: María José Moreno; Rosa Bosch; Rebeca Dieguez-Gonzalez; Silvana Novelli; Ana Mozos; Alberto Gallardo; Miguel Ángel Pavón; María Virtudes Céspedes; Albert Grañena; Miguel Alcoceba; Oscar Blanco; Marcos Gonzalez-Díaz; Jorge Sierra; Ramon Mangues; Isolda Casanova Journal: J Pathol Date: 2014-12-11 Impact factor: 7.996
Authors: Sonia López-Giral; Nuria E Quintana; María Cabrerizo; Manuel Alfonso-Pérez; Mónica Sala-Valdés; Valle Gómez Garcia De Soria; José María Fernández-Rañada; Elena Fernández-Ruiz; Cecilia Muñoz Journal: J Leukoc Biol Date: 2004-05-20 Impact factor: 4.962
Authors: Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger Journal: Theranostics Date: 2015-03-01 Impact factor: 11.556
Authors: Max Czajkowski; Daniel Kaemmerer; Jörg Sänger; Guido Sauter; Ralph M Wirtz; Stefan Schulz; Amelie Lupp Journal: BMC Cancer Date: 2022-07-07 Impact factor: 4.638
Authors: Franziska Lange; Daniel Kaemmerer; Julianne Behnke-Mursch; Wolfgang Brück; Stefan Schulz; Amelie Lupp Journal: J Cancer Res Clin Oncol Date: 2018-04-25 Impact factor: 4.553
Authors: Xiang Li; Daniel Heber; Tatjana Leike; Dietrich Beitzke; Xia Lu; Xiaoli Zhang; Yongxiang Wei; Markus Mitterhauser; Wolfgang Wadsak; Saskia Kropf; Hans J Wester; Christian Loewe; Marcus Hacker; Alexander R Haug Journal: Eur J Nucl Med Mol Imaging Date: 2017-09-21 Impact factor: 9.236
Authors: Alexander R Haug; Asha Leisser; Wolfgang Wadsak; Markus Mitterhauser; Sarah Pfaff; S Kropf; Hans-Juergen Wester; Marcus Hacker; Markus Hartenbach; Barbara Kiesewetter-Wiederkehr; Markus Raderer; Marius E Mayerhoefer Journal: Theranostics Date: 2019-05-27 Impact factor: 11.556